Q-omics provides the consensus-scored UBASH3B profile across patient tissues and cancer cell-line models. UBASH3B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, UBASH3B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, UBASH3B protein abundance shows 20,421 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, HNSC, and LSCC as cancer lineages where UBASH3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBASH3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBASH3B survival associations across molecular data types. UBASH3B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBASH3B RNA expression–survival associations across cancer types. High UBASH3B expression shows unfavorable associations in LGG, PAAD, LUSC, LIHC and BLCA, but favorable associations in SKCM. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for UBASH3B RNA expression.
This table summarizes UBASH3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for UBASH3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBASH3B shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, STAD, BLCA and KIRP. The HNSC box plot shows higher UBASH3B RNA expression in tumor versus normal tissue (log2 FC = +1.117, t-test p < 0.001).
This table shows molecular features associated with UBASH3B in patient tissues and cancer cell lines. In patient samples, UBASH3B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBASH3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
